Business Wire

Verimatrix Positioned as a Leader and Ace Performer in the 2025 SPARK Matrix TM for In-App Protection by QKS Group

7.5.2025 17:45:00 CEST | Business Wire | Press Release

Share

Regulatory News:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250507970501/en/

Verimatrix positioned as a Leader in the 2025 SPARK Matrix™ for In-App Protection by QKS Group. Verimatrix has been recognized for its comprehensive in-app protection capabilities, earning strong ratings across both Technology Excellence and Customer Impact in the latest SPARK Matrix™. The company has also been named an Ace Performer a recognition given to vendors that demonstrate revenue growth potential, partnership strategy, and customer acquisition—all evaluated over the last one-year period or since the previous SPARK Matrix assessment. The QKS Group SPARK Matrix™ provides competitive analysis & ranking of the leading In-App Protection vendors. For more information about Verimatrix, visit: https://www.verimatrix.com SPARK MatrixTM: In-App Protection, Q1 2025: https://qksgroup.com/market-research/spark-matrix-in-app-protection-q1-2025-8413

Verimatrix, (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced that QKS Group named Verimatrix a 2025 technology leader in the SPARK Matrix™: In-App Protection, 2025.

Ayush Patidar, Analyst at QKS Group, states, “Verimatrix XTD (Extended Threat Defense) offers a robust and unified approach to application security which combines zero-code protection, AI-driven threat detection, and real-time response across mobile, web, desktop and embedded platforms. Its seamless CI/CD and SIEM integration ensures that security is embedded during the application development phase. With features like Whitebox Cryptography and managed threat intelligence, Verimatrix XTD helps organizations to proactively defend against evolving threats while maintaining performance and user experience.”

The QKS Group SPARK Matrix™ includes a detailed analysis of the global market dynamics, major trends, vendor landscape, and competitive positioning. The study also provides a competitive analysis and ranking of the In-App Protection providers in the form of the SPARK Matrix™. The study also provides strategic information for users to evaluate different vendor capabilities, competitive differentiation, and market positions.

“It’s one thing to be recognized as a leader year after year—but being named an Ace Performer puts Verimatrix XTD in a league of its own,” said Jon Samsel, Head of Cybersecurity Business and Global Marketing at Verimatrix. “Verimatrix XTD isn’t just growing—we’re setting the pace for what modern app protection should look like.”

The study notes Verimatrix XTD’s strength as a truly comprehensive security suite that provides an AI/ML-driven anomaly detection system that continuously monitors app, device, and network behaviors to identify suspicious activities such as tampering, Man-in-the-Middle attacks, and overlay-based phishing attacks like accessibility malware. XTD detects high-risk behavior in the early stages, enabling organizations to block or mitigate threats in real time, strengthening fraud prevention and data protection while ensuring a seamless user experience.

Other noted strengths in the study include:

  • Zero-code injection technology allows security defenses to be embedded into applications at runtime and eliminates the need for manual code modifications or security SDKs.
  • Comprehensive environment checks that detect rooted/jailbroken devices, emulator usage, debugging tools, virtual environments, and other indicators of compromise.
  • Seamless integration with Security Information and Event Management (SIEM) solutions, allowing organizations to incorporate real-time app security insights into their broader cybersecurity monitoring framework.

About QKS Group
QKS Group is a global advisory and consulting firm focused on helping clients achieve business transformation goals with Strategic Business and Growth advisory services. At QKS Group, our vision is to become an integral part of our client’s business as a strategic knowledge partner. Our research and consulting deliverables are designed to provide comprehensive information and strategic insights for helping clients formulate growth strategies to survive and thrive in ever-changing business environments.For more information, visit www.qksgroup.com.

About Verimatrix
Verimatrix (Euronext Paris: VMX, FR0010291245) helps power the modern connected world with security made for people. We protect digital content, applications, and devices with intuitive, people-centered and frictionless security. Leading brands turn to Verimatrix to secure premium movies, live streaming sports, sensitive financial and healthcare data, mission-critical mobile applications, and much more. We enable the trusted connections our customers depend on to deliver compelling content and experiences to millions of consumers around the world. Verimatrix helps partners get to market faster, scale easily, protect valuable revenue streams, and win new business. Visit https://www.verimatrix.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250507970501/en/

Contacts

Verimatrix Investor:
Jean-François Labadie, Chief Financial Officer
finance@verimatrix.com

SEITOSEI.ACTIFIN
Michael Scholze
Michael.scholze@seitosei-actifin.com

Verimatrix Media:
Matthew Zintel
matthew.zintel@zintelpr.com

QKS Group Media:
Shraddha Roy
shraddha.r@qksgroup.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye